Literature DB >> 18940803

Unbiased screening for transcriptional targets of ZKSCAN3 identifies integrin beta 4 and vascular endothelial growth factor as downstream targets.

Lin Yang1, Li Zhang, Qiuyu Wu, Douglas D Boyd.   

Abstract

We previously described the novel zinc finger protein ZKSCAN3 as a new "driver" of colon cancer progression. To investigate the underlying mechanism and because the predicted structural features (tandem zinc fingers) are often present in transcription factors, we hypothesized that ZKSCAN3 regulates the expression of a gene(s) favoring tumor progression. We employed unbiased screening to identify a DNA binding motif and candidate downstream genes. Cyclic amplification and selection of targets using a random oligonucleotide library and ZKSCAN3 protein identified KRDGGG as the DNA recognition motif. In expression profiling, 204 genes were induced 2-29-fold, and 76 genes reduced 2-5-fold by ZKSCAN3. To enrich for direct targets, we eliminated genes under-represented (<3) for the ZKSCAN3 binding motif (identified by CAST-ing) in 2 kilobases of regulatory sequence. Up-regulated putative downstream targets included genes contributing to growth (c-Met-related tyrosine kinase (MST1R), MEK2; the guanine nucleotide exchanger RasGRP2, insulin-like growth factor-2, integrin beta 4), cell migration (MST1R), angiogenesis (vascular endothelial growth factor), and proteolysis (MMP26; cathepsin D; PRSS3 (protease serine 3)). We pursued integrin beta 4 (induced up to 6-fold) as a candidate target because it promotes breast cancer tumorigenicity and stimulates phosphatidyl 3-kinase implicated in colorectal cancer progression. ZKSCAN3 overexpression/silencing modulated integrin beta 4 expression, confirming the array analysis. Moreover, ZKSCAN3 bound to the integrin beta 4 promoter in vitro and in vivo, and the integrin beta 4-derived ZKSCAN3 motif fused upstream of a tk-Luc reporter conferred ZKSCAN3 sensitivity. Integrin beta 4 knockdown by short hairpin RNA countered ZKSCAN3-augmented anchorage-independent colony formation. We also demonstrate vascular endothelial growth factor as a direct ZKSCAN3 target. Thus, ZKSCAN3 regulates the expression of several genes favoring tumor progression including integrin beta 4.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18940803      PMCID: PMC2596387          DOI: 10.1074/jbc.M806965200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

1.  Computational identification of cis-regulatory elements associated with groups of functionally related genes in Saccharomyces cerevisiae.

Authors:  J D Hughes; P W Estep; S Tavazoie; G M Church
Journal:  J Mol Biol       Date:  2000-03-10       Impact factor: 5.469

2.  Cloning and characterization of the human beta4-integrin gene promoter and enhancers.

Authors:  A S Takaoka; T Yamada; M Gotoh; Y Kanai; K Imai; S Hirohashi
Journal:  J Biol Chem       Date:  1998-12-11       Impact factor: 5.157

Review 3.  Transcriptional regulation of vascular endothelial growth factor in cancer.

Authors:  Robyn M B Loureiro; Patricia A D'Amore
Journal:  Cytokine Growth Factor Rev       Date:  2005-02       Impact factor: 7.638

4.  Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer.

Authors:  Belinda E Peace; Kenya Toney-Earley; Margaret H Collins; Susan E Waltz
Journal:  Cancer Res       Date:  2005-02-15       Impact factor: 12.701

5.  Oncogenic K-ras stimulates Wnt signaling in colon cancer through inhibition of GSK-3beta.

Authors:  Jingnan Li; Yusuke Mizukami; Xiaobo Zhang; Won-Seok Jo; Daniel C Chung
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

6.  Overexpression of LMO4 induces mammary hyperplasia, promotes cell invasion, and is a predictor of poor outcome in breast cancer.

Authors:  Eleanor Y M Sum; Davendra Segara; Belinda Duscio; Mary L Bath; Andrew S Field; Robert L Sutherland; Geoffrey J Lindeman; Jane E Visvader
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-16       Impact factor: 11.205

7.  Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression.

Authors:  Daniele Calistri; Claudia Rengucci; Ian Seymour; Arturo Lattuneddu; Anna Maria Polifemo; Franco Monti; Luca Saragoni; Dino Amadori
Journal:  J Cell Physiol       Date:  2005-08       Impact factor: 6.384

Review 8.  TGF-beta signaling in tumor suppression and cancer progression.

Authors:  R Derynck; R J Akhurst; A Balmain
Journal:  Nat Genet       Date:  2001-10       Impact factor: 38.330

9.  NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia.

Authors:  Maya Dajee; Mirella Lazarov; Jennifer Y Zhang; Ti Cai; Cheryl L Green; Alan J Russell; M Peter Marinkovich; Shiying Tao; Qun Lin; Yoshiaki Kubo; Paul A Khavari
Journal:  Nature       Date:  2003-02-06       Impact factor: 49.962

10.  Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells.

Authors:  Jun Chung; Robin E Bachelder; Elizabeth A Lipscomb; Leslie M Shaw; Arthur M Mercurio
Journal:  J Cell Biol       Date:  2002-07-08       Impact factor: 10.539

View more
  26 in total

1.  The zinc finger transcription factor ZKSCAN3 promotes prostate cancer cell migration.

Authors:  Xingding Zhang; Yu Jing; Yang Qin; Sally Hunsucker; Huimin Meng; Jun Sui; Yelin Jiang; Li Gao; Gangli An; Nan Yang; Robert Z Orlowski; Lin Yang
Journal:  Int J Biochem Cell Biol       Date:  2012-04-16       Impact factor: 5.085

Review 2.  Biochemical and structural insights into mesotrypsin: an unusual human trypsin.

Authors:  Moh'd A Salameh; Evette S Radisky
Journal:  Int J Biochem Mol Biol       Date:  2013-09-13

3.  The amyloid precursor protein/protease nexin 2 Kunitz inhibitor domain is a highly specific substrate of mesotrypsin.

Authors:  Moh'd A Salameh; Jessica L Robinson; Duraiswamy Navaneetham; Dipali Sinha; Benjamin J Madden; Peter N Walsh; Evette S Radisky
Journal:  J Biol Chem       Date:  2009-11-17       Impact factor: 5.157

4.  ZKSCAN3 is a master transcriptional repressor of autophagy.

Authors:  Santosh Chauhan; Jinesh G Goodwin; Swati Chauhan; Ganiraju Manyam; Jing Wang; Ashish M Kamat; Douglas D Boyd
Journal:  Mol Cell       Date:  2013-02-21       Impact factor: 17.970

5.  Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma.

Authors:  L Yang; H Wang; S M Kornblau; D A Graber; N Zhang; J A Matthews; M Wang; D M Weber; S K Thomas; J J Shah; L Zhang; G Lu; M Zhao; R Muddasani; S-Y Yoo; K A Baggerly; R Z Orlowski
Journal:  Oncogene       Date:  2010-11-08       Impact factor: 9.867

6.  Determinants of affinity and proteolytic stability in interactions of Kunitz family protease inhibitors with mesotrypsin.

Authors:  Moh'd A Salameh; Alexei S Soares; Duraiswamy Navaneetham; Dipali Sinha; Peter N Walsh; Evette S Radisky
Journal:  J Biol Chem       Date:  2010-09-22       Impact factor: 5.157

7.  PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer.

Authors:  Alexandra Hockla; Erin Miller; Moh'd A Salameh; John A Copland; Derek C Radisky; Evette S Radisky
Journal:  Mol Cancer Res       Date:  2012-12       Impact factor: 5.852

8.  Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapy.

Authors:  Itay Cohen; Olumide Kayode; Alexandra Hockla; Banumathi Sankaran; Derek C Radisky; Evette S Radisky; Niv Papo
Journal:  Biochem J       Date:  2016-03-08       Impact factor: 3.857

9.  Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109.

Authors:  Alexandra Hockla; Derek C Radisky; Evette S Radisky
Journal:  Breast Cancer Res Treat       Date:  2009-12-25       Impact factor: 4.872

10.  A large scale multivariate parallel ICA method reveals novel imaging-genetic relationships for Alzheimer's disease in the ADNI cohort.

Authors:  Shashwath A Meda; Balaji Narayanan; Jingyu Liu; Nora I Perrone-Bizzozero; Michael C Stevens; Vince D Calhoun; David C Glahn; Li Shen; Shannon L Risacher; Andrew J Saykin; Godfrey D Pearlson
Journal:  Neuroimage       Date:  2012-01-08       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.